Samuel Paullin

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.

Cooley advised the underwriters in Vivid Seats’ $128 million follow-on offering. Vivid Seats is an online ticket marketplace connecting fans to live events and artists. As the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theaters and comedy, Vivid Seats operates in two segments – marketplace and resale. Lawyers Christina Roupas, Courtney Tygesson, Grady Chang, Sam Paullin, Leah Duncan and Adam Bloom led the Cooley team.

Cooley advised Geron Corporation, a late-stage biopharmaceutical company in California pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies, on its $227.8 million follow-on offering. Partners Chadwick Mills and Kristin VanderPas led the Cooley team.